CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol
Eun Kyung Lee, You Jin Lee, Young Joo Park, Jae Hoon Moon, Ka Hee Yi, Koon Soon Kim, Joo Hee Lee, Sun Wook Cho, Jungnam Joo, Yul Hwangbo, Sujeong Go, Do Joon Park
Endocrinol Metab. 2020;35(3):571-577.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.681

Excel Download

A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol
Eun Kyung Lee, You Jin Lee, Young Joo Park, Jae Hoon Moon, Ka Hee Yi, Koon Soon Kim, Joo Hee Lee, Sun Wook Cho, Jungnam Joo, Yul Hwangbo, Sujeong Go, Do Joon Park
Endocrinology and Metabolism. 2020;35(3):571-577   Crossref logo
Link1 Link2 Link3
Role of Radioactive Iodine for Remnant Ablation in Patients with Papillary Thyroid Cancer
Nicole M. Iniguez-Ariza, Suneetha Kaggal, Ian D. Hay
Management of Differentiated Thyroid Cancer. 2017;205-222   Crossref logo
Link1
Recombinant Human Thyroid Stimulating Hormone–Assisted Radioactive Iodine Remnant Ablation in Thyroid Cancer Patients at Intermediate to High Risk of Recurrence
Jonathan Hugo, Eyal Robenshtok, Ravinder Grewal, Steve Larson, R. Michael Tuttle
Thyroid. 2012;22(10):1007-1015   Crossref logo
Link1 Link2
Prediction of radioactive iodine remnant ablation failure in patients with differentiated thyroid cancer: A cohort study of 740 patients
Marin Prpic, Davor Kust, Ivan Kruljac, Lora Stanka Kirigin, Tomislav Jukic, Nina Dabelic, Ante Bolanca, Zvonko Kusic
Head & Neck. 2016;39(1):109-115   Crossref logo
Link1 Link2 Link3
Stimulated Thyroglobulin and Neck Ultrasonography Facilitates Postsurgical Radioactive Iodine Remnant Ablation Selection in Patients with Low-Risk Well-Differentiated Thyroid Carcinoma
Karen Gomez Hernandez, Daniel Etarsky, Steven Orlov, Paul G. Walfish
Thyroid. 2012;22(7):760-761   Crossref logo
Link1 Link2
Prospective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid Cancer
Furio Pacini
European Thyroid Journal. 2016;5(1):7-8   Crossref logo
Link1 Link2
Ablation of the thyroid remnant and 131 I dose in differentiated thyroid cancer
Suhail A.R. Doi, Nicholas J.Y. Woodhouse
Clinical Endocrinology. 2000;52(6):765-773   Crossref logo
Link1 Link2 Link3
Remnant Ablation, Adjuvant Treatment and Treatment of Locoregional Metastases with 131I
Douglas Van Nostrand
Thyroid Cancer. 2016;395-409   Crossref logo
Link1
Re: “Dynamic Risk Stratification for Predicting Recurrence in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy” by Park et al.: (Thyroid 2017;27:524–530)
Erfan Ayubi, Mark J.M. Sullman, Saeid Safiri
Thyroid. 2017;27(12):1582-1582   Crossref logo
Link1 Link2
Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros
Kenneth B. Ain
Endocrine. 2015;50(1):61-66   Crossref logo
Link1 Link2 Link3